Semax

What is Semax?

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). It was developed in a Russian academic environment as an analogue of the ACTH(4–10) fragment — part of adrenocorticotropic hormone that is associated with the stress response but does not itself carry the full hormonal activity.

In Russia, Semax is registered as a medicine for certain neurological indications. This is important context, but it does not mean it is approved in Croatia or other EU countries. For research laboratories it is relevant as a research compound with a rich but partly methodologically limited literature.

Proposed mechanisms

In preclinical studies, researchers have reported several effects:

• increased expression of BDNF (brain-derived neurotrophic factor);
• activation of the TrkB pathway, associated with neuronal survival;
• an effect on neuroplasticity and synaptic signalling;
• modulation of the stress response and inflammatory signalling pathways.

BDNF is an attractive target because it is involved in learning, memory and nerve regeneration. However, a distinction must be made between increased expression in a model and improved cognition in humans. The latter requires clinical trials with appropriate outcomes.

What does the human literature show?

Part of the literature originates from Russian clinical settings, often with small samples, different criteria and limited cross-checking. This does not mean the results are worthless, but it makes independent confirmation more difficult.

In international reviews, Semax is described as a promising but under-researched compound. For researchers, the key points are:

• a clear definition of the model (cell culture, animal, human);
• measurable cognitive or biological outcomes;
• blinded assessment and adequate control;
• independent replication.

You can read more about the Russian nootropic tradition in the article Semax and Selank.

How is it studied?

Studies have used various routes of application, most often intranasal. The route of administration significantly affects bioavailability and distribution in the brain, so results from different studies cannot simply be added together.

For laboratory use, the stability of the peptide, the pH of the solution and possible adsorption to materials must be considered. These are practical factors that often determine the success or failure of an experiment more than the compound itself.

Safety

Semax is not an approved medicine in the EU. Data on long-term safety in humans are limited. Research must consider possible effects on the hormonal axis and the nervous system, and ensure appropriate professional judgement.

Quality and storage

The specification declares a purity of ≥ 98 % (HPLC). Store the lyophilizate at −20 °C, protected from light and moisture. After reconstitution, follow the protocol and store at 2–8 °C.

Conclusion

Semax is one of the most recognisable Russian neuropeptides and an interesting subject for research into BDNF and neuroplasticity. Nevertheless, it remains a research compound with limited independent clinical evidence.